Christopher Ryan Sullivan - 08 Mar 2022 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Financial Officer
Signature
/s/ Donald R. Reynolds, by Power of Attorney
Issuer symbol
AVTX
Transactions as of
08 Mar 2022
Net transactions value
$0
Form type
4
Filing time
10 Mar 2022, 16:50:14 UTC
Previous filing
14 Dec 2021
Next filing
07 Oct 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +400,000 $0.000000 400,000 08 Mar 2022 Common Stock 400,000 $0.7000 Direct F1
transaction AVTX Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 08 Mar 2022 Common Stock 50,000 $0.7000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date.
F2 The stock option will vest in full on March 8, 2023, subject to the Reporting Person's continued service through the vesting date.